婴儿和性的多重命中模型:2025年更新
Aristea S Galanopoulou1,2,3, Wenzhu B Mowrey4, Wei Liu1
1Laboratory of Developmental Epilepsy, Saul R. Korey Department of Neurology, Albert Einstein College of Medicine, Bronx, New York, USA.
Epilepsia open
|October 14, 2025
概括
这项研究在小鼠模型中测试了婴儿和性综合征 (IESS) 的治疗方法,发现抗炎药物fingolimod和sivelestat显示出迅速减少. 然而,没有一项经过测试的疗法实现了显著的自由.
科学领域:
- 神经科学和药理学 神经科学和药理学
- 发育神经学 发育神经学
- 的研究研究.
背景情况:
- 婴儿和性综合征 (IESS) 是一种严重的发育性和性脑病,具有不良的神经发育结果.
- 现有的IESS治疗方法往往无效或耐受性差,需要开发新的治疗方法.
- 已经建立了IESS的多次击中鼠标模型,以选潜在的治疗药物用于.
研究的目的:
- 评估临床上可用的治疗方法 (6α-methylprednisolone,topiramate) 和研究化合物 (fingolimod,sivelestat,IGF-1(1-3) 的疗效和耐受性,在IESS的多次击中老鼠模型中.
- 评估这些药物对的频率和严重性的急性影响.
- 提供对已测试的治疗方法对它们对,发育缺陷和耐受性的影响进行比较评估.
主要方法:
- 多重击中IESS的老鼠模型是诱导在斯普拉格-道利老鼠通过脑内静脉多克索鲁比辛和皮质内脂多糖注入.
- 每天的评估包括体重,运动和发育的里程碑,以及的监测.
- 药物通过内注射或每日注射进行了发作后的治疗,并使用混合线性模型分析了频率.
主要成果:
- 6α-methylprednisolone显示比托皮拉更一致地减少了的频率.
- 芬戈利莫德和西维莱斯塔特显示了的快速,短期减少,而西维莱斯塔特显示了更持久的效果.
- IGF-1 ((1-3) 对频率的影响很小,没有任何治疗可以实现显著的自由或>50%的减少.
结论:
- 多重打击的老鼠模型有效地模拟了IESS特征的耐药.
- 在这个模型中,抗炎/免疫调节剂,如fingolimod和sivelestat,可能会快速减少.
- 需要进一步的研究来开发更有效的IESS治疗方法,因为目前的治疗方法在这个模型中显示出有限的疗效.
相关概念视频
01:13Seizures: Classification
1.4K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.4K
01:24Epilepsy and Seizures: Overview
1.2K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.2K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
822
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
822
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
1.2K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.2K